NCT07159009View on ClinicalTrials.gov

A Study of GB261 in Systemic Sclerosis

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

September 4, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

July 31, 2027

Conditions

Systemic Sclerosis (SSc)

Interventions

DRUG

Biological: GB261

GB261 will be dosed according to the protocol

All Listed Sponsors

lead

Ruijin Hospital

OTHER